诺和诺德赢得重大法律胜利:多款司美格鲁肽和诺和泰的配制版药物被禁售

新浪财经
25 Apr

查看最新行情诺和诺德(Novo Nordisk)取得了一场重大的法律胜利,这在很大程度上限制了配制药店营销或销售该制药商的畅销减肥药司美格鲁肽(Wegovy)和糖尿病治疗药物诺和泰(Ozempic)的更便宜且未经批准的仿制版本。当地时间周四晚些时候,得克萨斯州的一名联邦法官驳回了配制药店的一项请求,该请求试图在针对这些药物短缺的法律质疑仍在进行期间,继续生产诺和泰和司美格鲁肽的仿制版药物。这一裁决...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10